Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Incidence and Therapeutic Implications of Germline TP53 Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort

Laura Rachele Bettini, Claudia Saitta, Barbara Buldini, Geertruij Te Kronnie, Stefano Rebellato, Daniela Silvestri, Elena Barisone, Andrea Pession, Marco Rabusin, Concetta Micalizzi, Franco Locatelli, MD PhD, Carmelo Rizzari, Maria Grazia Valsecchi, PhD, Andrea Biondi, MD, Grazia Fazio, Giovanni Cazzaniga, PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-142729

Published: 2020

Journal Articles

NUTM1 -Rearranged Infant and Pediatric B Cell Precursor Acute Lymphoblastic Leukemia: A Good Prognostic Subtype Identified in a Collaborative International Study

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-139376

Published: 2020

Journal Articles

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141236

Published: 2020

Journal Articles

Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134303

Published: 2020

Journal Articles

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Blood (2019) 134 (Supplement_1): 1351.

https://doi.org/10.1182/blood-2019-126523

Published: 2019

Journal Articles

Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts

Maria Caterina Rotiroti, PhD, Chiara Buracchi, PhD, Silvia Arcangeli, PhD, Chiara F Magnani, PhD, Claudia Cappuzzello, PhD, Zsuzsanna Izsvak, PhD, Stefania Galimberti, PhD, Maria Grazia Valsecchi, PhD, Giuseppe Dastoli, MD, Marta Serafini, PhD, Ettore Biagi, MD, Andrea Biondi, MD, Sarah Tettamanti, PhD

Blood (2019) 134 (Supplement_1): 2665.

https://doi.org/10.1182/blood-2019-130399

Published: 2019

Journal Articles

Transient Switch to Myeloid Lineage in Acute Lymphoblastic Leukemia during Induction Therapy: The Role of CD371 Expression and Implication for Minimal Residual Disease Detection

Elena Varotto, MD PhD, Margarita Maurer-Granofszky, PhD, Daniela Silvestri, Pamela Scarparo, PhD, Ester Mejstrikova, MD PhD, Monika Brüggemann, Giovanni Cazzaniga, PhD, Valentino Conter, MD, Ondrej Hrusak, MD PhD, Giuseppe Gaipa, PhD, Angela Schumich, Maria Grazia Valsecchi, PhD, Giuseppe Basso, MD PhD, Michael Dworzak, MD, Barbara Buldini, MD PhD

Blood (2019) 134 (Supplement_1): 377.

https://doi.org/10.1182/blood-2019-127287

Published: 2019

Journal Articles

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Carmelo Rizzari, Anja Moericke, MD, Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Daniela Silvestri, Georg Mann, MD, Felix Niggli, MD, Luciano Dalla-Pozza, MBBS FRACP, Jan Stary, Prof., MD PhD, Sarah Elitzur, MD, Gunnar Cario, MD, Franco Locatelli, MD, Joachim Boos, MD, Massimo Zucchetti, PharmD, Andrea Biondi, MD, Martin Schrappe, MD PhD

Blood (2019) 134 (Supplement_1): 2589.

https://doi.org/10.1182/blood-2019-123448

Published: 2019

Journal Articles

Prognostic Value of Minimal Residual Disease Measured By Flow Cytometry in Two Cohorts of Infants with Acute Lymphoblastic Leukemia Treated with MLL-Baby and Interfant Protocols in Large Multicenter Networks

Blood (2019) 134 (Supplement_1): 2747.

https://doi.org/10.1182/blood-2019-130210

Published: 2019

Journal Articles

Results of a Multicentre, Randomized, Controlled Open-Label Study on the Use of Anti-T-Lymphocyte Globulin (ATLG) and Rituximab for Immunomodulation of Graft-Versus-Host Disease (GvHD) and Graft Failure (GF) in Patients with Non-Malignant Disorders

Mattia Algeri, MD, Stefania Galimberti, PhD, Maria Ester Bernardo, MD PhD, Attilio Rovelli, MD, Marco Zecca, MD, Giorgio La Nasa, MD, Sarah Marktel, MD, Pietro Merli, MD, Alice Bertaina, MD PhD, Daria Pagliara, MD PhD, Emilia Boccieri, MD, Francesca Del Bufalo, MD, Stefania Gaspari, MD, Giulia Capitoli, Maria Grazia Valsecchi, PhD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 3280.

https://doi.org/10.1182/blood-2019-128925

Published: 2019

Journal Articles

Lentiviral Hematopoietic Stem and Progenitor Cell Gene Therapy for Wiskott-Aldrich Syndrome (WAS): Up to 8 Years of Follow up in 17 Subjects Treated Since 2010

Blood (2019) 134 (Supplement_1): 3346.

https://doi.org/10.1182/blood-2019-124665

Published: 2019

Journal Articles

Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia

Grazia Fazio, Silvia Bresolin, Claudia Saitta, Daniela Silvestri, Elena Vendramini, Chiara Palmi, Silvia Rigamonti, Marta Galbiati, Manuel Quadri, Stefano Mecca, Angela Maria Savino, Michela Bardini, Andrea Grioni, Maria Grazia Valsecchi, PhD, Geertruy te Kronnie, Andrea Biondi, MD, Giovanni Cazzaniga, PhD

Blood (2019) 134 (Supplement_1): 745.

https://doi.org/10.1182/blood-2019-128509

Published: 2019

Journal Articles

Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Blood (2018) 132 (Supplement 1): 655.

https://doi.org/10.1182/blood-2018-99-112854

Published: 2018

Journal Articles

Effects of the Switch to Generic Imatinib in a Cohort of 109 Italian CML Patients - the Gims Study

Maria Gemelli, MD, Chiara Elena, MD, Margherita Maffioli, MD, Cristina Bucelli, MD, Marianna Rossi, MD, Mattia Bacciocchi, Elena Maria Elli, MD, Maria Grazia Valsecchi, PhD, Laura Antolini, PhD, Carlo Gambacorti-Passerini, MD

Blood (2018) 132 (Supplement 1): 4266.

https://doi.org/10.1182/blood-2018-99-115208

Published: 2018

Journal Articles

Activin A, a Potential Key Factor of the Malignant Bone Marrow Niche, Enhances B-Cell Precursor-Acute Lymphoblastic Leukemic Cell Migratory and Invasive Properties

Erica Dander, PhD, Federica Portale, PhD, Daniela Silvestri, Giulia Cricrì, Silvia Bresolin, PhD, Stefania Gaspari, Barbara Russo, Monica Lupi, Paolo Ubezio, Geertruy te Kronnie, Maria Grazia Valsecchi, PhD, Franco Locatelli, Carmelo Rizzari, MD, Andrea Biondi, MD, Giovanna D'Amico, BSc, PhD MSc

Blood (2018) 132 (Supplement 1): 1296.

https://doi.org/10.1182/blood-2018-99-116668

Published: 2018

Journal Articles

Flow Cytometric Measurement of the Initial In Vivo Response to Prednisone Provides New Prognostic Information in Childhood Acute Lymphoblastic Leukemia (ALL)

Giuseppe Gaipa, PhD, Oscar Maglia, Simona Sala, Bsc, Noemi Marino, Daniela Silvestri, Maria Grazia Valsecchi, PhD, Andrea Biondi, MD, Valentino Conter, MD

Blood (2018) 132 (Supplement 1): 2827.

https://doi.org/10.1182/blood-2018-99-116782

Published: 2018

Journal Articles

Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia

Irene Della Starza, PhD, Vittorio Nunes, Federica Lovisa, Daniela Silvestri, Marzia Cavalli, PhD, Andrea Garofalo, Mimma Campeggio, Lucia Anna De Novi, PhD, Carlotta Oggioni, Andrea Biondi, MD, Anna Guarini, PhD, Maria Grazia Valsecchi, PhD, Valentino Conter, MD, Giuseppe Basso, MD, Robin Foà, MD, Giovanni Cazzaniga, PhD

Blood (2018) 132 (Supplement 1): 1544.

https://doi.org/10.1182/blood-2018-99-117954

Published: 2018

Journal Articles

A Treatment Protocol with Imatinib and Intensive Chemotherapy for Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia Patients: A Single-Arm, Intergroup Study (EsPhALL 2010-2014)

Andrea Biondi, MD, Virginie Gandemer, MDPhD, Myriam Campbell, MD, Anders Castor, MD PhD, Rob Pieters, MD PhD, Paola De Lorenzo, PhD, Veronica Leoni, MD, Jan Stary, Gabriele Escherich, MD, Chi Kong Li, MD, Giovanni Cazzaniga, PhD, Helene Cave, PharmD, PhD, Silja Roettgers, PhD, Valentino Conter, MD, Vaskar Saha, MD PhD, Martin Schrappe, MD PhD, Maria Grazia Valsecchi, PhD

Blood (2017) 130 (Supplement 1): 97.

https://doi.org/10.1182/blood.V130.Suppl_1.97.97

Published: 2017

Journal Articles

Immunomodulatory Interventions Based on Minimal Residual Disease before and after Transplantation for Childhood Acute Lymphoblastic Leukemia

Adriana Balduzzi, MD, Lucia Di Maio, MD, Daniela Silvestri, MS, Simona Songia, BS, Giulia Prunotto, MD, Sonia Bonanomi, MD, Attilio Rovelli, MD, Andrea Biondi, MD, Giovanni Cazzaniga, Maria Grazia Valsecchi, PhD

Blood (2016) 128 (22): 3480.

https://doi.org/10.1182/blood.V128.22.3480.3480

Published: 2016

Journal Articles

Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)

Martin Schrappe, MD, Martin Zimmermann, PhD, Anja Möricke, MD, Georg Mann, MD, Maria Grazia Valsecchi, PhD, Claus R. Bartram, PhD, Andrea Biondi, MD, Renate Panzer-Grümayer, MD, Rita Beier, MD, Gunnar Cario, Franco Locatelli, MD, Giuseppe Basso, Felix Niggli, MD, Maurizio Aricò, MD, Valentino Conter

Blood (2016) 128 (22): 4.

https://doi.org/10.1182/blood.V128.22.4.4

Published: 2016

NARROW

Incidence and Therapeutic Implications of Germline TP53 Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort

NUTM1 -Rearranged Infant and Pediatric B Cell Precursor Acute Lymphoblastic Leukemia: A Good Prognostic Subtype Identified in a Collaborative International Study

Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity

Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A -Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Preclinical Assessment of Non-Virally Engineered CD33.CAR Cytokine-Induced Killer (CIK) Cells in Chemoresistant AML Patient-Derived Xenografts

Transient Switch to Myeloid Lineage in Acute Lymphoblastic Leukemia during Induction Therapy: The Role of CD371 Expression and Implication for Minimal Residual Disease Detection

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Prognostic Value of Minimal Residual Disease Measured By Flow Cytometry in Two Cohorts of Infants with Acute Lymphoblastic Leukemia Treated with MLL-Baby and Interfant Protocols in Large Multicenter Networks

Results of a Multicentre, Randomized, Controlled Open-Label Study on the Use of Anti-T-Lymphocyte Globulin (ATLG) and Rituximab for Immunomodulation of Graft-Versus-Host Disease (GvHD) and Graft Failure (GF) in Patients with Non-Malignant Disorders

Lentiviral Hematopoietic Stem and Progenitor Cell Gene Therapy for Wiskott-Aldrich Syndrome (WAS): Up to 8 Years of Follow up in 17 Subjects Treated Since 2010

Pre-Clinical Efficacy of the Novel Kinase Inhibitor Nintedanib on PAX5 Fusion Genes in Pediatric Ph-like B-Cell Precursor Acute Lymphoblastic Leukemia

Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Effects of the Switch to Generic Imatinib in a Cohort of 109 Italian CML Patients - the Gims Study

Activin A, a Potential Key Factor of the Malignant Bone Marrow Niche, Enhances B-Cell Precursor-Acute Lymphoblastic Leukemic Cell Migratory and Invasive Properties

Flow Cytometric Measurement of the Initial In Vivo Response to Prednisone Provides New Prognostic Information in Childhood Acute Lymphoblastic Leukemia (ALL)

Digital-Droplet PCR, an Accurate Method for IG/TR PCR-MRD Stratification in Childhood Acute Lymphoblastic Leukemia

A Treatment Protocol with Imatinib and Intensive Chemotherapy for Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia Patients: A Single-Arm, Intergroup Study (EsPhALL 2010-2014)

Immunomodulatory Interventions Based on Minimal Residual Disease before and after Transplantation for Childhood Acute Lymphoblastic Leukemia

Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only